Mesothelioma News and Research RSS Feed - Mesothelioma News and Research

Mesothelioma is a form of cancer that is almost always caused by previous exposure to asbestos. In this disease, malignant cells develop in the mesothelium, a protective lining that covers most of the body's internal organs. Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, or have been exposed to high levels of asbestos fibers.
New NCCN Imaging AUC released for eight new cancers

New NCCN Imaging AUC released for eight new cancers

The National Comprehensive Cancer Network, a Centers for Medicare & Medicaid Services-approved provider-led entity for imaging appropriate use criteria, continues to build its library of AUC and has published NCCN Imaging Appropriate Use Criteria for eight new cancer types. Launched in June 2016, NCCN Imaging AUC currently are available for 20 cancer types. [More]
Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Cancer remains a leading cause of death worldwide, and the global cancer burden is expected to increase by 70 percent over the next two decades. [More]
Novel combination therapy slows cancer growth in patients with advanced solid tumors

Novel combination therapy slows cancer growth in patients with advanced solid tumors

A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors. [More]
NCCN educational resources provide insight for patients with Mycosis Fungoides

NCCN educational resources provide insight for patients with Mycosis Fungoides

Mycosis Fungoides is a very rare form of lymphoma affecting approximately 1,000 people per year in the United States. [More]
PD surgery improves quality of life in patients with malignant pleural mesothelioma

PD surgery improves quality of life in patients with malignant pleural mesothelioma

Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of life. [More]
AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology in Chicago, USA, on 3-7 June 2016. [More]
NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges. [More]
International scientists discuss new treatments for non small cell lung cancer

International scientists discuss new treatments for non small cell lung cancer

More than 30 prominent international scientists gathered to discuss the state-of-the-art, as well as promising future approaches for the treatment of lung cancer at the stunning 17th century Borgo San Luigi, in Monteriggion, in the heart of the Tuscany countryside. [More]
New drug shows promise against mesothelioma

New drug shows promise against mesothelioma

A new drug is showing promise as a treatment for mesothelioma - one of the most lethal cancers of all. [More]
ONCOblot test shows promise in early detection of malignant mesothelioma

ONCOblot test shows promise in early detection of malignant mesothelioma

MorNuCo Laboratories of West Lafayette, Indiana, and their ONCOblot Test recently completed a retrospective clinical trial focusing on the early detection of malignant mesothelioma, with the exciting results that the ONCOblot test detected a molecular marker that is indicative of the presence of mesothelioma, 4-10 years in advance of clinical symptoms appearing. [More]
Bevacizumab extends survival of pleural mesothelioma patients

Bevacizumab extends survival of pleural mesothelioma patients

Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standard treatment according to phase III trial findings published inĀ The Lancet. [More]
Four unrelated families share identical BAP1 mutation that causes several cancers

Four unrelated families share identical BAP1 mutation that causes several cancers

University of Hawai'i Cancer Center researchers discovered members of four families, apparently unrelated and living in different states across the US, shared the identical mutation of a gene called BAP1 that causes mesothelioma, melanoma, renal carcinoma and other cancers. [More]
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). [More]
Research finding offers hope for more powerful aspirin-like drugs

Research finding offers hope for more powerful aspirin-like drugs

Researchers have found that salicylic acid targets the activities of HMGB1, an inflammatory protein associated with a wide variety of diseases, offering hope that more powerful aspirin-like drugs may be developed. [More]
VA Hospital performs first successful heated chemotherapy bath on a patient with mesothelioma

VA Hospital performs first successful heated chemotherapy bath on a patient with mesothelioma

Nationalmesotheliomaclaims.com, a comprehensive website that provides people with mesothelioma and their families with in-depth information and free resources about the disease, is excited to report that a VA Hospital in Roxbury, MA has just performed the first successful heated chemotherapy bath. [More]
Atezolizumab may change treatment strategies for refractory lung cancer patients

Atezolizumab may change treatment strategies for refractory lung cancer patients

Atezolizumab is set to substantially change treatment strategies for patients with refractory lung cancer, according to Dr Martin Reck, Chief Oncology Physician in the Department of Thoracic Oncology, Hospital Grosshansdorf, Germany. Reck's comments came as the results from the POPLAR and BIRCH studies showing the first results of efficacy with atezolizumab across lines were presented at the European Cancer Congress 2015 (ECC 2015) in Vienna, Austria. [More]

Mesothelioma.us releases some critical information about how to avoid mesothelioma

Mesothelioma.us, a free online resource that provides people with mesothelioma and their families with educational articles and other information about the disease, has just released some critical information about how to beat mesothelioma. [More]

Mesothelioma website posts encouraging news about mesothelioma

Mesothelioma.us, a free online resource filled with helpful information for people who have been diagnosed with mesothelioma, is now reporting that mesothelioma is more beatable than previously believed. [More]
New statistical model may help predict patients more likely to benefit from surgical treatment for mesothelioma

New statistical model may help predict patients more likely to benefit from surgical treatment for mesothelioma

A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma (MPM), according to an article in the September 2015 issue of the Annals of Thoracic Surgery. [More]
Penns' Abramson Cancer Center rated as 'exceptional' by NCI

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

The University of Pennsylvania's Abramson Cancer Center (ACC) has received an "exceptional" rating by the National Cancer Institute during an extensive peer-review process for its five-year competitive research support grant. The rating is the highest possible for an NCI cancer center. [More]
Advertisement
Advertisement